Other GLP-1 medications: Including Zepbound injection, Wegovy, Ozempic, Saxenda, Victoza, Byetta, Bydureon, or compounded GLP-1 formularies
Glycaemic efficacy Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (MD [95% CI]: 21.61 mmol/mol [23.26 to 19.97] [1.96% (2.11 to 1.82)]), followed by tirzepatide 10 mg (20.19 mmol/mol [21.89 to 18.48] [1.84% (1.99 to 1.69)]), semaglutide 2.0 mg (17.74 mmol/mol [22.03 to 13.45] [1.59% (1.95 to 1.22)]), tirzepatide 5 mg (17.60 mmol/mol [19.36 to 15.84] [1.60% (1.75 to 1.44)]), semaglutide 1.0 mg (15.25 mmol/mol [16.73 to 13.77] [1.39% (1.52 to 1.26)]) and semaglutide 0.5 mg (12.00 mmol/mol [13.74 to 10.26] [1.09% (1.24 to 0.94)]) (Fig
Discussing these options with a healthcare provider can help determine the most suitable approach for each individual
The FDA made this determination after receiving numerous complaints from patients, providers, manufacturers, compounders, and other stakeholders that these drugs were unavailable on the market
)
